Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
Geburtshilfe und Frauenheilkunde · 01.06.2023 · 83 (06) · 673-685
DOI: 10.1055/a-2073-1887 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.06.2023. Verfasst von Volkmar Müller und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis.
Abstract (Originalsprache)
In patients with existing ovarian function, there are some special aspects to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-negative (HR pos./HER2 neg.) breast cancer. Treatment options include tamoxifen with or without a GnRH analog, and aromatase inhibitors with a GnRH analog. Furthermore, ovarian function is affected by previous chemotherapy. Both aromatase inhibitors (+GnRH analogs) and GnRH analogs in combination with tamoxifen are supposed to be indicated for patients at increased risk of recurrence. However, national and international guidelines and therapy recommendations do not provide a clear definition of intermediate or high risk; as a result, therapy decisions are often made for each patient on an individual basis. This is also reflected in the considerable variability at national and international levels, e.g., with regard to the use of aromatase inhibitors + GnRH analogs. This review summarizes the data on completed studies (e.g., SOFT, TEXT, EBCTCG meta-analyses) and the current multigene testing studies (TailorX, RxPonder, ADAPT), discusses the rationale for current studies (e.g., CLEAR-B), and looks ahead to future questions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
- Novartis Pharma GmbH, Nürnberg, Germany.
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
- Department of Gynecology and Gynecological Oncology, Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany.
- Universitäts-Frauenklinik Mainz, Mainz, Germany.
Förderung
- Novartis
Zitieren
APA
Müller, V., Fasching, P. A., Nabieva, N., Fehm, T. N., Thill, M., Schmidt, M., Kühn, T., Banys-Paluchowski, M., Belleville, E., Juhasz-Böss, I., Untch, M., Kolberg, H. C., Harbeck, N., Aktas, B., Stickeler, E., Kreuzeder, J., Hartkopf, A. D., Janni, W., & Ditsch, N. (2023). Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare. Geburtshilfe und Frauenheilkunde, 83(06), 673-685. https://doi.org/10.1055/a-2073-1887
Vancouver
Müller V, Fasching PA, Nabieva N, Fehm TN, Thill M, Schmidt M, et al. Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare. Geburtshilfe und Frauenheilkunde. 2023;83(06):673-685. doi:10.1055/a-2073-1887
BibTeX
@article{Mller2023,
author = {Müller, Volkmar and Fasching, Peter A and Nabieva, Naiba and Fehm, Tanja N and Thill, Marc and Schmidt, Marcus and Kühn, Thorsten and Banys-Paluchowski, Maggie and Belleville, Erik and Juhasz-Böss, Ingolf and Untch, Michael and Kolberg, Hans-Christian and Harbeck, Nadia and Aktas, Bahriye and Stickeler, Elmar and Kreuzeder, Julia and Hartkopf, Andreas D and Janni, Wolfgang and Ditsch, Nina},
title = {Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare},
journal = {Geburtshilfe und Frauenheilkunde},
year = {2023},
volume = {83},
number = {06},
pages = {673--685},
doi = {10.1055/a-2073-1887}
}
EUVIMED